KEQU KEWAUNEE SCIENTIFIC CORP /DE/
Laboratory Apparatus & Furniture · Nasdaq · SEC CIK 55529 · Fiscal year ends 04/30
Financial factors as of 2026-07-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.3%
TTM net income YoY-33.1%
TTM EPS YoY-33.2%
Revenue 3-yr CAGR8.1%
Net income 3-yr CAGR27.6%
Margins
Gross margin28.6%
Operating margin5.4%
Net margin3.0%
FCF margin3.9%
EBITDA margin7.7%
Returns
ROE11.6%
ROA4.5%
ROIC (approx.)13.1%
Asset turnover1.50x
Leverage & solvency
Liabilities / assets56.1%
Debt / equity0.25x
Current ratio2.20x
Interest coverage4.39x
Cash quality & payout
Operating cash flow / net income1.80x
Accruals ratio-3.6%
Payout ratio—
Capex / revenue1.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-04-30 | FY20252025-04-30 |
|---|---|---|
| Income statement | ||
| Revenue | $282.00M | $240.47M |
| Cost of revenue | $201.56M | $171.62M |
| Gross profit | $80.44M | $68.86M |
| R&D expense | $898,000 | $919,000 |
| Operating income | $16.71M | $17.76M |
| Interest expense | $3.86M | $3.21M |
| Pretax income | $13.73M | $14.79M |
| Income tax | $3.27M | $3.20M |
| Net income | $9.62M | $11.40M |
| EBITDA | $23.00M | $22.52M |
| EPS (basic) | 3.36 | 3.98 |
| EPS (diluted) | 3.22 | 3.83 |
| Weighted avg. shares (diluted) | 2.98M | 2.98M |
| Balance sheet | ||
| Cash & equivalents | $9.95M | $17.16M |
| Receivables | $58.74M | $62.38M |
| Inventory | $30.53M | $32.85M |
| Current assets | $105.40M | $118.36M |
| PP&E, net | $22.37M | $23.17M |
| Goodwill | $12.49M | $12.49M |
| Intangibles | $16.29M | $17.83M |
| Total assets | $178.31M | $194.65M |
| Current liabilities | $48.35M | $53.71M |
| Short-term debt | $5.00M | $3.00M |
| Long-term debt | $15.08M | $34.69M |
| Total debt | $20.08M | $37.69M |
| Total liabilities | $101.50M | $128.41M |
| Shareholders' equity | $74.72M | $64.46M |
| Net debt | $10.13M | $20.52M |
| Shares outstanding | 2.87M | 2.84M |
| Cash flow statement | ||
| Operating cash flow | $18.63M | $14.78M |
| Capital expenditure | $3.94M | $2.17M |
| Free cash flow | $14.70M | $12.62M |
| Investing cash flow | -$3.94M | -$30.90M |
| Financing cash flow | -$19.33M | $7.41M |
| Depreciation & amortization | $6.28M | $4.76M |
| Stock-based compensation | $2.13M | $1.44M |
| Share buybacks | $0 | $1.60M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.